Literature DB >> 29552709

Use of calcimimetics in children with normal kidney function.

Judith Sebestyen VanSickle1, Tarak Srivastava1,2, Uri S Alon3.   

Abstract

The calcium-sensing receptor (CaSR) plays an important role in the homeostasis of serum ionized calcium by regulating parathyroid hormone (PTH) secretion and tubular calcium handling. Calcimimetics, which act by allosteric modulation of the CaSR, mimic hypercalcemia resulting in suppression of PTH release and increase in calciuria. Mostly used in children to treat secondary hyperparathyroidism associated with advanced renal failure, we have shown that calcimimetics can also be successfully used in children with bone and mineral disorders in which elevated PTH plays a detrimental role in skeletal pathophysiology in the face of normal kidney function. The current review briefly discusses the role of the CaSR and calcimimetics in calcium homeostasis, and then addresses the potential applications of calcimimetics in children with normal kidney function with disorders in which suppression of PTH is beneficial.

Entities:  

Keywords:  Calcimimetics; Calcium-sensing receptor; Hyperparathyroidism; Parathyroid hormone; Rickets

Mesh:

Substances:

Year:  2018        PMID: 29552709     DOI: 10.1007/s00467-018-3935-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  56 in total

1.  Cinacalcet as adjunctive therapy for hereditary 1,25-dihydroxyvitamin D-resistant rickets.

Authors:  Tarak Srivastava; Uri S Alon
Journal:  J Bone Miner Res       Date:  2013-05       Impact factor: 6.741

Review 2.  Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.

Authors:  Katherine Wesseling-Perry; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2013-02-05       Impact factor: 3.714

3.  Primary hyperparathyroidism in Chinese children and adolescents: A single-centre experience at Peking Union Medical College Hospital.

Authors:  Wenbo Wang; Jing Kong; Min Nie; Yan Jiang; Mei Li; Weibo Xia; Xunwu Meng; Xiaoping Xing; Ou Wang
Journal:  Clin Endocrinol (Oxf)       Date:  2017-09-13       Impact factor: 3.478

4.  Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.

Authors:  Munro Peacock; John P Bilezikian; Preston S Klassen; Matthew D Guo; Stewart A Turner; Dolores Shoback
Journal:  J Clin Endocrinol Metab       Date:  2004-11-02       Impact factor: 5.958

5.  Effect of the calcimimetic NPS R-467 on furosemide-induced nephrocalcinosis in the young rat.

Authors:  Anirut Pattaragarn; John Fox; Uri S Alon
Journal:  Kidney Int       Date:  2004-05       Impact factor: 10.612

6.  Effects of parathyroid hormone and 1,25-dihydroxyvitamin D3 on tubular handling of phosphate in hypophosphatemic rickets.

Authors:  U Alon; J C Chan
Journal:  J Clin Endocrinol Metab       Date:  1984-04       Impact factor: 5.958

Review 7.  Hypophosphatemia: the common denominator of all rickets.

Authors:  Dov Tiosano; Ze'ev Hochberg
Journal:  J Bone Miner Metab       Date:  2009-06-06       Impact factor: 2.626

8.  Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism.

Authors:  M R Pollak; E M Brown; Y H Chou; S C Hebert; S J Marx; B Steinmann; T Levi; C E Seidman; J G Seidman
Journal:  Cell       Date:  1993-12-31       Impact factor: 41.582

Review 9.  New aspect of renal phosphate reabsorption: the type IIc sodium-dependent phosphate transporter.

Authors:  Ken-ichi Miyamoto; Mikiko Ito; Sawako Tatsumi; Masashi Kuwahata; Hiroko Segawa
Journal:  Am J Nephrol       Date:  2007-08-07       Impact factor: 3.754

10.  Utility of Cinacalcet in Familial Hypocalciuric Hypercalcemia.

Authors:  Bipin Kumar Sethi; V Sri Nagesh; Jayant Kelwade; Harsh Parekh; Vaibhav Dukle
Journal:  Indian J Endocrinol Metab       Date:  2017 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.